伊沙佐米-话题@MedSci

#伊沙佐米#

7篇内容 | 927人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2190377, encodeId=68f521903e7ff, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=12ab111e84e7' target=_blank style='color:#2F92EE;'>#来那度胺暴露#</a>, objectTitle=【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果, objectType=article, longId=815280, objectId=9d6981528062, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-hospital-corridor-with-medical-staff-and-PHNLKBC.jpg, objectUrl=/article/show_article.do?id=9d6981528062, replyNumber=0, likeNumber=19, createdTime=2024-03-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9d6981528062, moduleTitle=【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6981528062)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2187826, encodeId=2fbe218e826be, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a> <a href='/topic/show?id=25e99031628' target=_blank style='color:#2F92EE;'>#衰弱#</a> <a href='/topic/show?id=3c9e1105319f' target=_blank style='color:#2F92EE;'>#NDMM#</a>, objectTitle=【EClinicalMedicine】含伊沙佐米方案治疗老年衰弱NDMM的中国前瞻性研究, objectType=article, longId=813569, objectId=ab5281356966, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=ab5281356966, replyNumber=0, likeNumber=27, createdTime=2024-02-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=ab5281356966, moduleTitle=【EClinicalMedicine】含伊沙佐米方案治疗老年衰弱NDMM的中国前瞻性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab5281356966)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2185893, encodeId=e3f22185893b8, content=<a href='/topic/show?id=391935910a2' target=_blank style='color:#2F92EE;'>#华氏巨球蛋白血症#</a> <a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a> <a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=【BJH】全口服！伊布替尼联合伊沙佐米治疗华氏巨球蛋白血症的梅奥II期研究, objectType=article, longId=812250, objectId=6ff981225099, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=6ff981225099, replyNumber=0, likeNumber=38, createdTime=2024-02-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=6ff981225099, moduleTitle=【BJH】全口服！伊布替尼联合伊沙佐米治疗华氏巨球蛋白血症的梅奥II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ff981225099)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2117668, encodeId=cacb211e6689a, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>联合<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>和<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>治疗复发或难治性<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870], objectType=guider, longId=22614, objectId=1d7071c00299e514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=1d7071c00299e514, replyNumber=2, likeNumber=77, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1d7071c00299e514, moduleTitle=2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870], moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=1d7071c00299e514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526057, encodeId=4e17152605e9b, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！, objectType=article, longId=215762, objectId=968f215e627f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968f215e627f, replyNumber=0, likeNumber=39, createdTime=2021-08-17, rootId=0, userName=vividelife, userId=b2b311689214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968f215e627f, moduleTitle=J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968f215e627f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526056, encodeId=8fd3152605691, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=Blood：口服伊沙佐米-来那度胺-地塞米松治疗不能移植的新确诊多发性骨髓瘤, objectType=article, longId=213768, objectId=981b213e68a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=981b213e68a9, replyNumber=0, likeNumber=37, createdTime=2021-07-07, rootId=0, userName=vividelife, userId=b2b311689214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=981b213e68a9, moduleTitle=Blood：口服伊沙佐米-来那度胺-地塞米松治疗不能移植的新确诊多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=981b213e68a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, objectType=article, longId=212622, objectId=2be02126223c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be02126223c, replyNumber=0, likeNumber=33, createdTime=2021-06-13, rootId=0, userName=vividelife, userId=b2b311689214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be02126223c, moduleTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be02126223c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526054, encodeId=bafc15260544d, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性, objectType=article, longId=211096, objectId=5efc211096c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5efc211096c3, replyNumber=0, likeNumber=34, createdTime=2021-05-12, rootId=0, userName=vividelife, userId=b2b311689214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5efc211096c3, moduleTitle=JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5efc211096c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526053, encodeId=5c221526053ea, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=口服伊沙佐米提升骨髓瘤患者治疗依从性, objectType=article, longId=121583, objectId=3c371215839c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c371215839c, replyNumber=0, likeNumber=35, createdTime=2017-11-29, rootId=0, userName=vividelife, userId=b2b311689214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c371215839c, moduleTitle=口服伊沙佐米提升骨髓瘤患者治疗依从性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c371215839c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526052, encodeId=013a15260527d, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=【广告】多发性骨髓瘤新药伊沙佐米出炉, objectType=article, longId=86238, objectId=1c468623871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c468623871, replyNumber=0, likeNumber=56, createdTime=2017-01-01, rootId=0, userName=vividelife, userId=b2b311689214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c468623871, moduleTitle=【广告】多发性骨髓瘤新药伊沙佐米出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c468623871)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊沙佐米

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #地塞米松# #伊沙佐米# #达雷妥尤单抗# #来那度胺暴露#

【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果

2024-03-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#伊沙佐米# #衰弱# #NDMM#

【EClinicalMedicine】含伊沙佐米方案治疗老年衰弱NDMM的中国前瞻性研究

2024-02-17发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#华氏巨球蛋白血症# #伊布替尼# #伊沙佐米#

【BJH】全口服！伊布替尼联合伊沙佐米治疗华氏巨球蛋白血症的梅奥II期研究

2024-02-04发表于陕西省

lifestar (审核中...)

前往app查看评论内容

#伊沙佐米#联合#来那度胺#和#地塞米松#治疗复发或难治性#多发性骨髓瘤#

2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870]

2023-03-05发表于上海

vividelife (审核中...)

前往app查看评论内容

#伊沙佐米#

J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！

2021-08-17

vividelife (审核中...)

前往app查看评论内容

#伊沙佐米#

Blood：口服伊沙佐米-来那度胺-地塞米松治疗不能移植的新确诊多发性骨髓瘤

2021-07-07

vividelife (审核中...)

前往app查看评论内容

#伊沙佐米#

JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析

2021-06-13

vividelife (审核中...)

前往app查看评论内容

#伊沙佐米#

JCO：伊沙佐米+达雷木单抗+地塞米松用于多发性骨髓瘤体弱患者的疗效和安全性

2021-05-12

vividelife (审核中...)

前往app查看评论内容

#伊沙佐米#

口服伊沙佐米提升骨髓瘤患者治疗依从性

2017-11-29

vividelife (审核中...)

前往app查看评论内容

#伊沙佐米#

【广告】多发性骨髓瘤新药伊沙佐米出炉

2017-01-01

科室
- - 订阅+
  - 更多科室
工具
服务